Buscar

Mostrando ítems 1-10 de 48

Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C

Esposito, Isabella; Marciano, Sebastian; Trinks, Julieta (Taylor & Francis, 2018-06)

Introduction: Many reports have evaluated the clinical efficacy and safety of the fixed-dose all-oral combination of daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO), which was approved in Japan in December 2016 for the ...

Cost effectiveness of Daclatasvir/Asunaprevir versus Peginterferon/Ribavirin and protease inhibitors for the treatment of Hepatitis C genotype 1b naive patients in Chile

Vargas, Constanza L.; Espinoza Sepúlveda, Manuel Antonio; Giglio, Andres; Soza, Alejandro (2015)

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

Sacramento, Carolina Q.; Rodrigues, Natalia Fintelman; Temerozo, Jairo Ramos; Silva, Aline de Paula Dias da; Dias, Suelen da Silva Gomes; Silva, Carine dos Santos da; Ferreira, André C.; Mattos, Mayara; Pão, Camila R. R.; Freitas, Caroline S. de; Soares, Vinicius Cardoso; Hoelz, Lucas Villas Bôas; Fernandes, Tácio Vinício Amorim; Castelo Brando, Frederico Silva; Bastos, Mônica Macedo; Boechat, Nubia; Saraiva, Felipe B.; Ferreira, Marcelo Alves; Jockusch, Steffen; Wang, Xuanting; Tao, Chuanjuan; Chien, Minchen; Xie, Wei; Patel, Dinshaw J.; Garzia, Aitor; Tuschi, Thomas; Russo, James J.; Rajoli, Rajith K. R.; Pedrosa, Carolina S. G. P; Vitória, Gabriela; Souza, Leticia Rocha Quintino; Silva, Livia Goto; Guimaraes, Marilia Zaluar; Rehen, Stevens K.; Owen, Andrew; Bozza, Fernando A.; Bou-Habib, Dumith Chequer; Ju, Jingyue; Bozza, Patrícia Torres; Souza, Thiago Moreno L. (Oxford University Press, 2021)

Treatment Of Hepatitis C Virus Genotype 3 Infection With Direct-acting Antiviral Agents

Zanaga; L. P.; Miotto; N.; Mendes; L. C.; Stucchi; R. S. B.; Vigani; A. G. (Assoc Bras Divulg CientificaSão Paulo, 2016)

A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir

Universidade Estadual Paulista (Unesp); Univ Leeds; Universidade de São Paulo (USP) (Microbiology Soc, 2021-01-01)

Hepatitis C virus (HCV) genotype 3 presents a high level of both baseline and acquired resistance to direct-acting antivirals (DAAs), particularly those targeting the NS5A protein. To understand this resistance we studied ...

Avaliação da eficácia e segurança do daclatasvir e sofosbuvir versus alfapeginterferona 2A no tratamento da hepatite C crônica

BARROS, Luciana Tavares de Carvalho (Universidade Federal de PernambucoUFPEBrasilPrograma de Pos Graduacao em Gestao e Economia da Saude, 2018)

nsaio clínico randomizado para avaliação da eficácia do tratamento com sofosbuvir mais daclatasvir ou simeprevir no tratamento de pacientes com hepatite C crônica genótipo 1 não cirróticos

Pott Junior, Henrique [UNIFESP] (Universidade Federal de São Paulo (UNIFESP), 2017-12-06)

ABSTRACT Introduction: This study investigated the safety and efficacy of simeprevir plus sofosbuvir (SOF+SIM) or daclatasvir plus sofosbuvir (SOF+DCV) regimen in a randomized, open-label, non-inferiority trial in patients ...

B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin

Ridruejo, Ezequiel; Cheinquer, Hugo; Marciano, Sebastián; Mendizabal, Manuel; Piñero, Federico; Wolff, Fernando H.; de Araujo, Alexandre; Coelho Borges, Silvia; Kliemann, Dimas; Fleck, Alfeu; de Maman, Ítalo; Nader, Lysandro A.; Garrastazul, Patricia; Bermúdez, Carla; Haddad, Leila; Gadano, Adrián Carlos; Silva, Marcelo (Wiley Blackwell Publishing, Inc, 2019-05-29)

Real-world data evaluating the effectiveness of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) treatment have been reported from different regions. Our aim was to evaluate the effectiveness and clinical outcomes ...

A novel substitution in NS5A enhances resistance of hepatitis C virus genotype 3 to daclatasvir (vol 102, 001496, 2021)